Intranasal EV vaccine protected mice from H5N1, H7N9
edited by Alexander Pol
A novel vaccine platform has been developed to induce broad, protective immunity against numerous influenza virus infections, showing promise as an effective mucosal vaccine strategy, according to a study published by researchers in the Institute for Biomedical Sciences at Georgia State University.
The study published in
the journal ACS Nano used cell-derived extracellular vesicles (EVs) as a vaccine
platform to display various human and avian influenza hemagglutinins (HAs) in
an upside-down manner on the EV surfaces. The inverted HA tends to present the
conserved HA stalk to the immune system to induce cross-protective influenza
immunity while hiding the highly variable HA head to avoid strain-specific
immunity.
The investigators used mice to evaluate cellular and mucosal
immune responses induced by the multiple HA EV vaccines. HA is a major
influenza surface glycoprotein. EVs are natural nanoparticles that facilitate
cell-to-cell communications.
The researchers found that EV-based
inverted HA vaccines hold great promise for developing universal
influenza vaccines that target a mucosal route.
Developing innovative vaccine platforms and delivery
strategies to induce protective immunity against diverse influenza virus
strains in the respiratory tract is crucial for preventing influenza infection
and transmission in potential epidemics and pandemics.










.png)



